Dexcom Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Dexcom Inc 's ROA in the third quarter of 2026?
Dexcom Inc achieved a return on average assets (ROA) of 15.47 % in its third quarter of 2026 a new company high.

ROA has improved compared to 14.9% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 61 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 420, from total ROA ranking in the second quarter of 2026 at 569.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-16.22 %	-11.22 %	-0.89 %	0.04 %	18.43 %
Y / Y Net Income Change	-3.07 %	39.49 %	89.28 %	76.2 %	110.85 %
Net Income (TTM) in million	993	1,001	930	836	721
Return On Assets (TTM)	15.47 %	14.9 %	13.44 %	12.05 %	10.39 %
DXCM's Total Ranking	# 420	# 569	# 598	# 744	# 783
Total Assets (TTM) in million	6,239	6,455	6,633	6,340	7,447
Seq. Total Assets Change	-3.36 %	-2.68 %	4.63 %	-14.86 %	2.41 %
Seq. Net Income Change	9.69 %	25.71 %	-25.36 %	-5.81 %	57.84 %

DXCM's 5 Years Annual ROA >> Back to DXCM Management Effectiveness >> Compare DXCM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 13
Sector	# 62
Overall	# 329

Return On Assets Statistics
High	Average	Low
15.47 %	-7.66 %	-51.59 %
(Sep 30 2026)		(Sep 30 2012)

Financial Statements
Dexcom Inc 's Assets	$ 6,239 million	DXCM's Balance sheet
Dexcom Inc 's Income	$ 275 million	Quarterly DXCM's Income Statement
DXCM's Income by Division		See DXCM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-1.3 %	3.7 %	16.6 %	11.22 %	13.77 %
Total Assets in million	6,340	6,424	6,195	5,313	4,777
Y / Y Net Income Change	45.14 %	6.41 %	58.7 %	120.56 %	-68.66 %
Net Income in million	836	576	542	341	155
Annual Return On Assets	13.19 %	8.97 %	8.74 %	6.42 %	3.24 %

DXCM's 5 Years Annual ROA >> Back to DXCM Management Effectiveness >> Compare DXCM ROA to its Competitors

Comment on DXCM's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 13.19 % compared to prior year, due to annual net income growth of 45.14 % to $836.30 million, and due to decline of value in Dexcom Inc 's assets by -1.3 % to $6,339.90 million, compared to $6,339.90 a year before.

More Return On Assets Ratios
DXCM's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DXCM's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DXCM's Competitors
Subscribers only: Roa for Dexcom Inc 's Suppliers
Subscribers only: Return On Assets for DXCM's Customers

You may also want to know
DXCM's Roi	DXCM's Inventory Turnover Ratio	DXCM's Growth Rates	DXCM's Dividend Comparisons
	DXCM's Profitability Ratios	DXCM's Asset Turnover Ratio	DXCM's Dividend Growth
DXCM's Roe	DXCM's Valuation Ratios	DXCM's Financial Strength Ratios	DXCM's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %

Date modified: 2026-10-30T13:08:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.